Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

ABSTRACT:

Objective

To describe the clinical outcomes associated with the use of checkpoint inhibitor therapy in recurrent ovarian malignancy.

Methods

Women with recurrent ovarian cancer treated with an immune checkpoint inhibitor between 1/2012 and 8/2017 were included. RECIST criteria determined disease status, and immune related adverse events (irAE) were graded per trial protocols. Predictors of response, irAE, progression free survival (PFS) and overall survival (OS) were investigated.

Results

Forty-four women were included with a median age of 53 years, median of 4 prior lines of chemotherapy, and most commonly high grade serous pathology (59.1%). 3 patients had partial response and 3 had pseudoprogression, for a response rate of 14.2%. In subset analysis of high grade se

SUBMITTER: Hinchcliff E 

PROVIDER: S-EPMC6281778 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature